Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
作者信息
Li Ziming, Lu Shun
机构信息
Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
J Clin Oncol. 2023 Feb 20;41(6):1172-1175. doi: 10.1200/JCO.22.02278. Epub 2023 Jan 9.
PMID:36623229
Abstract
摘要
Zotero 插件